-
Seminars in oncology · Apr 1997
ReviewEfficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
- H H Hansen and J B Sørensen.
- Rigshospitalet-National University Hospital of Copenhagen, Denmark.
- Semin. Oncol. 1997 Apr 1; 24 (2 Suppl 7): S7-38-S7-41.
AbstractWithin the last 5 years, gemcitabine, a new nucleoside analogue, has been evaluated in several international phase II trials in patients with advanced non-small cell lung cancer (NSCLC). Five trials have evaluated 438 patients. Gemcitabine was administered intravenously in four trials on days 1, 8, and 15 at a dose of 800 to 1,700 mg/m2 every 4 weeks. In the fifth trial, gemcitabine was given at a dose of 90 mg/m2 twice weekly x 3 every 4 weeks. The overall response rate was 21% (95% confidence limits, 16% to 25%) with a median survival of 4 weeks (range, 26 to 46 weeks). The median duration of response varied from 26 to 49 weeks. The activity of gemcitabine in NSCLC, together with its modest toxicity and distinct mode of action, suggest the need for further trials of gemcitabine in combination with other chemotherapeutic agents in the treatment of NSCLC.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..